265 related articles for article (PubMed ID: 21974695)
41. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
42. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
Papatheofanis FJ; McKenzie RS; Mody SH; Suruki RY; Piech CT
Curr Med Res Opin; 2006 May; 22(5):837-42. PubMed ID: 16709305
[TBL] [Abstract][Full Text] [Related]
43. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
Milovanov IuS; Milovanova LIu
Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
[TBL] [Abstract][Full Text] [Related]
44. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
Berns JS
Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
[TBL] [Abstract][Full Text] [Related]
45. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
[TBL] [Abstract][Full Text] [Related]
46. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
[TBL] [Abstract][Full Text] [Related]
47. A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin.
Kamar N; Guitard J; Ribes D; Esposito L; Rostaing L
Exp Clin Transplant; 2008 Dec; 6(4):271-5. PubMed ID: 19338488
[TBL] [Abstract][Full Text] [Related]
48. Myocardial disease, anemia, and erythrocyte-stimulating proteins in chronic kidney disease.
Foley RN
Rev Cardiovasc Med; 2005; 6 Suppl 3():S27-34. PubMed ID: 16340936
[TBL] [Abstract][Full Text] [Related]
49. Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease.
Suzuki M; Hada Y; Akaishi M; Hiroe M; Aonuma K; Tsubakihara Y; Akizawa T
Int Heart J; 2012; 53(4):238-43. PubMed ID: 22878802
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
[TBL] [Abstract][Full Text] [Related]
51. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
Toto RD; Pichette V; Navarro J; Brenner R; Carroll W; Liu W; Roger S
Am J Nephrol; 2004; 24(4):453-60. PubMed ID: 15331889
[TBL] [Abstract][Full Text] [Related]
52. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
[TBL] [Abstract][Full Text] [Related]
53. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
Carrera F; Oliveira L; Maia P; Mendes T; Ferreira C
Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
[TBL] [Abstract][Full Text] [Related]
54. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis.
Parfrey PS; Lauve M; Latremouille-Viau D; Lefebvre P
Clin J Am Soc Nephrol; 2009 Apr; 4(4):755-62. PubMed ID: 19339417
[TBL] [Abstract][Full Text] [Related]
55. Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease.
Cianciaruso B; Ravani P; Barrett BJ; Levin A;
J Nephrol; 2008; 21(6):861-70. PubMed ID: 19034870
[TBL] [Abstract][Full Text] [Related]
56. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
Mix TC; Brenner RM; Cooper ME; de Zeeuw D; Ivanovich P; Levey AS; McGill JB; McMurray JJ; Parfrey PS; Parving HH; Pereira BJ; Remuzzi G; Singh AK; Solomon SD; Stehman-Breen C; Toto RD; Pfeffer MA
Am Heart J; 2005 Mar; 149(3):408-13. PubMed ID: 15864229
[TBL] [Abstract][Full Text] [Related]
57. Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials.
Locatelli F; de Francisco A; Deray G; Fliser D; Armstrong G; Dougherty FC; Ehrhard P
Nephron Clin Pract; 2014; 128(3-4):323-32. PubMed ID: 25503585
[TBL] [Abstract][Full Text] [Related]
58. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.
Locatelli F; Aljama P; Canaud B; Covic A; De Francisco A; Macdougall IC; Wiecek A; Vanholder R;
Nephrol Dial Transplant; 2010 Sep; 25(9):2846-50. PubMed ID: 20591813
[TBL] [Abstract][Full Text] [Related]
59. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.
Phrommintikul A; Haas SJ; Elsik M; Krum H
Lancet; 2007 Feb; 369(9559):381-8. PubMed ID: 17276778
[TBL] [Abstract][Full Text] [Related]
60. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
Singh AK
J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]